Latest news and press releases about Merck & Co., Inc. (MRK): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes.
Price
| Price | $144.30 |
| Market Cap | $356.4B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 115.44 |
| Price / Book | 8.51 |
| EV / EBITDA | 29.14 |
| Dividend Yield | 2.36% |
Profitability
| Return on Equity | 6.60% |
| Return on Invested Capital | 5.62% |
| Return on Assets | 2.44% |
| Gross Margin | 75.38% |
| Operating Margin | 16.65% |
| Net Margin | 4.78% |
Related companies: ABT · AMGN · AZN · GILD · GSK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of MRK: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks